ABBV241101P155000
- 0.01
- 0.000.00%
AbbVie Newsroom
Eli Lilly's Zepbound Sales, Pfizer Wants in on Weight Loss Drugs, AbbVie's Big Deal: Pharma News Round up
AbbVie's Deal for Alzheimer's Antibody Raises Curtain for Roche News on Wednesday -- Barrons.com
Thursday, Halloween Market Falls in Scary Reaction to Earnings | Wall Street Today
NYSE New 52-Week Highs And Lows
Recent Dividend Declarations
AbbVie Price Target Raised to $200.00/Share From $195.00 by UBS
AbbVie Is Maintained at Neutral by UBS
Market Analysis: AbbVie And Competitors In Biotechnology Industry
Halloween Market Falls, Scared of Meta and Microsoft CapEx | Live Stock
Express News | Abbvie : Raymond James Raises Target Price to $221 From $200
Cantor Fitzgerald Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $240
Morgan Stanley Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $231
A Quick Look at Today's Ratings for AbbVie(ABBV.US), With a Forecast Between $205 to $240
AbbVie Analyst Ratings
AbbVie, EvolveImmune To Develop Multispecific Biologics For Multiple Targets In Oncology
Today's Analyst Rating | Microsoft Price Target Raised to $548 by Morgan Stanley, Alphabet-C Price Target Raised to $220 by Barclays
Express News | Abbvie Inc - Evolveimmune to Receive $65 Million Upfront, up to $1.4 Billion in Milestones
Express News | Abbvie and Evolveimmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics
AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics
Morgan Stanley Raises Price Target on AbbVie to $231 From $218, Keeps Overweight Rating